Vendor Intelligence Report: Pure Tested Peptides

Executive summary

Across 7 Finnrick lab tests, Pure Tested Peptides shows 3 pass / 4 fail — an overall pass rate of 43%. The record is small but not uniform: CJC-1295 is the only tested product with a directionally favorable record, while PT-141 and Tesamorelin are the weak spots. The full report shows why that distinction matters, including how ratings compress under stricter grading rather than resolving into a simple vendor-wide verdict.

The public-facing story is also newer and messier than the brand language suggests. Formation, BBB, WHOIS, Wayback, and registry records point away from a clean Florida operating-company footprint and toward a New Jersey nutraceutical trail. The site presents “Ben Perez” and biomedical-style credentials; the record set includes a BBB managing-member name, a separate author profile with a “Brian” bridge, and an archived phone number that leads into a different consumer-business footprint.

The most important documentation issue is the COA system. Reviewed Pure Tested Peptides COAs lack the markers buyers expect from independent third-party retail-batch testing — named lab, accreditation, analyst contact, and chain of custody — while repeating anonymous bulk-manufacturer language and 500g–800g quantities. Finnrick testing shows some real product is shipping, but the vendor’s own paperwork does not establish that the vial a buyer receives was independently tested.

Buyer recourse is the other red flag. The report documents Venmo/Zelle discounting alongside detailed review complaints alleging non-delivery, ghost shipment, quantity mismatch, and relabeling. It also maps a near-identical lookalike domain with a different address and infrastructure, plus GLP-adjacent marketing without the supplier-compliance evidence a serious buyer should demand.

Inside the full report:

• Appendix A Finnrick laboratory data with per-product pass/fail rates, trajectories, and methodology-divergence charts
• Florida, New Jersey, BBB, WHOIS, Wayback, and registry records tracing the operating footprint
• Ben Perez / Brian Pe attribution analysis using public profiles, BBB data, and archived phone-number evidence
• Side-by-side COA review showing anonymous bulk-manufacturer template features across multiple products
• Trustindex complaint analysis covering Venmo non-delivery, relabeling, quantity mismatch, and ghost-shipment claims
• Lookalike-domain and infrastructure comparison for totalpuretested-peptides.com

Risk assessment

• Operator-identity and legal-accountability risk — high: BBB lists Brian Pe / Next Level Nutra while the site presents Ben Perez and a Lutz, FL footprint; Florida entity searches returned no PTP or Next Level Nutra registration.
• Credential and expertise-claim risk — high: PTP claims AAMI / ACCE / RAPS / ASQ-certified professionals, but supplied public profiles verify nursing and animal-biology backgrounds, not those certifications.
• COA / third-party-testing integrity risk — high: Posted COAs lack lab attribution / accreditation and use anonymous manufacturer boilerplate with 500g-800g bulk quantities.
• Payment and fulfillment-recourse risk — high: PTP discounts Venmo / Zelle payments; Trustindex complaints report non-delivery and ghost shipment with limited chargeback recourse.
• Product-quality risk (PT-141 and Tesamorelin) — high: Finnrick testing shows PT-141 at 0 pass / 2 fail and Tesamorelin at 1 pass / 2 fail; CJC-1295 does not carry this concern at 2 pass / 0 fail.
• Packaging/relabeling integrity risk — medium: Trustindex review evidence describes damaged packaging and a label applied over another label; chain of custody cannot be verified.
• Copycat / brand-confusion risk — medium: totalpuretested-peptides.com copies PTP layout but has separate registration / infrastructure; PTP does not provide authoritative anti-counterfeit or channel verification.
• Regulatory and import-chain risk for GLP-adjacent products — medium: PTP markets Tirzepatide / Retatrutide / GLP-adjacent items without documented FDA Green List supplier evidence in the Import Alert 66-80 context.